Clinical Trial Update: Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of tabelecleucel in combination with pembrolizumab for Epstein-Barr virus-associated nasopharyngeal carcinoma was terminated, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus-associated Nasopharyngeal Carcinoma
• Nasopharyngeal Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tabelecleucel (tabelecleucel)

Snippet

Sponsor: Atara Biotherapeutics | Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-11-14